FDA Approves New Immunotherapy for Endometrial Cancer FDA Approves New Immunotherapy for Endometrial Cancer

The accelerated approval for dostarlimab is for use in patients with recurrent or advanced endometrial cancers with deficient mismatch repair (dMMR).FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news